Brainstorm Cell Therapeutics Inc. - Understand $bcli stock

$BCLI Market Cap: $9.297 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$14.23M

TTM

Current Assets

$364.0K

Q3 2024

Current Liabilities

$7.082M

Q3 2024

Current Ratio

5.14%

Q3 2024

Total Assets

$2.025M

Q3 2024

Total Liabilities

$8.082M

Q3 2024

Book Value

-$6.057M

Q3 2024

Cash

$168.0K

Q3 2024

P/E

-0.6534

Nov 29, 2024 EST

Free Cash Flow

-$3.286M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Selling, General & Admin	$10.69M	$10.87M	$9.304M	$9.360M	$5.800M	$5.770M	$4.020M	$2.830M	$3.590M	$2.650M	$2.130M	$1.750M	$2.210M	$1.540M	$1.570M	$1.630M	$2.990M	$2.140M
YoY Change	-1.59%	16.79%	-0.6%	61.38%	0.52%	43.53%	42.05%	-21.17%	35.47%	24.41%	21.71%	-20.81%	43.51%	-1.91%	-3.68%	-45.48%	39.72%	23.7%
% of Gross Profit
Research & Development	$10.75M	$13.96M	$15.24M	$22.33M	$17.20M	$8.293M	$977.0K	$2.250M	$4.949M	$4.772M	$2.917M	$1.770M	$1.690M	$1.050M	$180.0K	$1.640M	$1.930M	$740.0K
YoY Change	-23.0%	-8.4%	-31.77%	29.79%	107.45%	748.82%	-56.58%	-54.54%	3.71%	63.59%	64.8%	4.73%	60.95%	483.33%	-89.02%	-15.03%	160.81%	-11.9%
% of Gross Profit
Depreciation & Amortization	$265.0K	$285.0K	$260.0K	$219.0K	$164.0K	$110.0K	$85.00K	$77.00K	$87.00K	$106.0K	$97.00K	$157.0K	$150.0K	$160.0K	$170.0K	$150.0K	$100.0K	$60.00K
YoY Change	-7.02%	9.62%	18.72%	33.54%	49.09%	29.41%	10.39%	-11.49%	-17.92%	9.28%	-38.22%	4.67%	-6.25%	-5.88%	13.33%	50.0%	66.67%	50.0%
% of Gross Profit
Operating Expenses	$10.75M	$13.96M	$15.24M	$22.33M	$17.20M	$8.293M	$977.0K	$2.250M	$4.949M	$7.421M	$5.043M	$3.518M	$3.890M	$2.590M	$1.750M	$3.270M	$4.920M	$2.880M
YoY Change	-23.0%	-8.4%	-31.77%	29.79%	107.45%	748.82%	-56.58%	-54.54%	-33.31%	47.15%	43.35%	-9.56%	50.19%	48.0%	-46.48%	-33.54%	70.83%	12.06%
Operating Profit	-$21.44M	-$24.82M	-$24.54M	-$31.68M	-$23.00M	-$14.06M	-$4.999M	-$5.083M	-$8.536M	-$7.421M	-$4.899M	-$3.425M
YoY Change	-13.63%	1.15%	-22.55%	37.75%	63.56%	181.32%	-1.65%	-40.45%	15.02%	51.48%	43.04%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Interest Expense	$4.694M													$189.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$447.0K	$545.0K	$82.00K	-$130.0K	-$250.0K	$120.0K	$50.00K	$100.0K	$50.00K	-$1.830M	$140.0K	$90.00K	-$20.00K	$190.0K	-$30.00K	-$200.0K	-$1.330M	-$1.030M
YoY Change	-182.02%	564.63%	-163.08%	-48.0%	-308.33%	140.0%	-50.0%	100.0%	-102.73%	-1407.14%	55.56%	-550.0%	-110.53%	-733.33%	-85.0%	-84.96%	29.13%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Pretax Income	-$17.19M	-$24.28M	-$24.46M	-$31.81M	-$4.378M	-$3.617M	-$2.532M	-$1.451M	-$2.842M	-$3.789M	-$1.205M	-$1.197M	-$3.910M	-$2.400M	-$1.780M	-$3.470M	-$6.240M	-$3.910M
YoY Change	-29.18%	-0.74%	-23.12%	626.61%	21.04%	42.85%	74.5%	-48.94%	-24.99%	214.44%	0.67%	-69.39%	62.92%	34.83%	-48.7%	-44.39%	59.59%	52.14%
Income Tax							$0.00	$0.00	$0.00	$0.00	$0.00	$5.000K	$10.00K	$20.00K	$0.00	$0.00	$0.00	$20.00K
% Of Pretax Income
Net Earnings	-$17.19M	-$24.28M	-$24.46M	-$31.81M	-$23.25M	-$13.95M	-$4.952M	-$4.982M	-$8.488M	-$9.246M	-$4.899M	-$3.430M	-$3.918M	-$2.419M	-$1.781M	-$3.472M	-$6.244M	-$3.317M
YoY Change	-29.18%	-0.74%	-23.12%	36.8%	66.71%	181.66%	-0.6%	-41.31%	-8.2%	88.73%	42.83%	-12.46%	61.97%	35.82%	-48.7%	-44.39%	88.24%	-82.39%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.40	-$0.66	-$0.68	-$1.07
Diluted Earnings Per Share	-$0.40	-$0.66	-$0.68	-$1.07	-$1.061M	-$697.5K	-$263.6K	-$266.9K	-$461.2K	-$677.2K	-$456.2K	-$374.0K	-$489.4K	-$407.4K	-$436.3K	-$1.061M	-$3.200M	-$2.481M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Cash & Short-Term Investments	$1.300M	$2.983M	$22.09M	$41.94M	$570.0K	$7.060M	$7.760M	$9.990M	$15.96M	$8.540M	$3.500M	$4.090M	$1.920M	$90.00K	$0.00	$0.00	$90.00K	$60.00K
YoY Change	-56.42%	-86.5%	-47.32%	7257.89%	-91.93%	-9.02%	-22.32%	-37.41%	86.89%	144.0%	-14.43%	113.02%	2033.33%			-100.0%	50.0%
Cash & Equivalents	$1.300M	$772.0K	$18.86M	$37.83M	$540.0K	$940.0K	$2.480M	$550.0K	$430.0K	$4.250M	$3.500M	$1.320M	$1.920M	$90.00K	$0.00	$0.00	$90.00K	$60.00K
Short-Term Investments	$0.00	$2.211M	$3.238M	$4.110M	$30.00K	$6.120M	$5.270M	$9.440M	$15.53M	$4.290M	$0.00	$2.770M
Other Short-Term Assets	$548.0K	$32.00K	$1.100M	$1.000M	$440.0K	$1.190M	$1.200M	$150.0K	$70.00K	$30.00K	$30.00K	$50.00K	$70.00K	$60.00K	$70.00K	$50.00K	$80.00K	$60.00K
YoY Change	1612.5%	-97.09%	10.0%	127.27%	-63.03%	-0.83%	700.0%	114.29%	133.33%	0.0%	-40.0%	-28.57%	16.67%	-14.29%	40.0%	-37.5%	33.33%
Inventory
Prepaid Expenses
Receivables	$51.00K	$91.00K	$0.00	$220.0K	$2.270M	$1.920M	$570.0K	$310.0K	$760.0K	$1.010M	$910.0K	$740.0K	$310.0K	$430.0K	$10.00K	$10.00K	$100.0K	$20.00K
Other Receivables	$0.00	$0.00	$86.00K	$80.00K	$90.00K	$90.00K	$100.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.899M	$3.106M	$23.28M	$43.24M	$3.360M	$10.27M	$9.620M	$10.44M	$16.79M	$9.580M	$4.450M	$4.870M	$2.300M	$580.0K	$90.00K	$60.00K	$260.0K	$130.0K
YoY Change	-38.86%	-86.66%	-46.16%	1186.9%	-67.28%	6.76%	-7.85%	-37.82%	75.26%	115.28%	-8.62%	111.74%	296.55%	544.44%	50.0%	-76.92%	100.0%
Property, Plant & Equipment	$2.102M	$5.322M	$5.970M	$7.990M	$3.140M	$650.0K	$390.0K	$300.0K	$270.0K	$310.0K	$260.0K	$250.0K	$310.0K	$420.0K	$580.0K	$740.0K	$740.0K	$490.0K
YoY Change	-60.5%	-10.85%	-25.28%	154.46%	383.08%	66.67%	30.0%	11.11%	-12.9%	19.23%	4.0%	-19.35%	-26.19%	-27.59%	-21.62%	0.0%	51.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments													$20.00K	$0.00	$10.00K	$10.00K	$10.00K	$10.00K
YoY Change														-100.0%	0.0%	0.0%	0.0%
Other Assets	$207.0K	$23.00K	$27.00K	$30.00K	$30.00K	$310.0K	$1.410M	$30.00K	$20.00K	$20.00K	$20.00K	$20.00K	$110.0K	$90.00K	$90.00K	$60.00K	$80.00K	$90.00K
YoY Change	800.0%	-14.81%	-10.0%	0.0%	-90.32%	-78.01%	4600.0%	50.0%	0.0%	0.0%	0.0%	-81.82%	22.22%	0.0%	50.0%	-25.0%	-11.11%
Total Long-Term Assets	$2.309M	$5.345M	$5.997M	$8.020M	$3.170M	$960.0K	$1.800M	$330.0K	$290.0K	$330.0K	$280.0K	$270.0K	$440.0K	$510.0K	$670.0K	$820.0K	$820.0K	$590.0K
YoY Change	-56.8%	-10.87%	-25.22%	153.0%	230.21%	-46.67%	445.45%	13.79%	-12.12%	17.86%	3.7%	-38.64%	-13.73%	-23.88%	-18.29%	0.0%	38.98%
Total Assets	$4.208M	$8.451M	$29.28M	$51.26M	$6.530M	$11.23M	$11.42M	$10.77M	$17.08M	$9.910M	$4.730M	$5.140M	$2.740M	$1.090M	$760.0K	$880.0K	$1.080M	$720.0K
YoY Change
Accounts Payable	$4.954M	$6.224M	$3.700M	$5.420M	$14.68M	$4.550M	$1.420M	$350.0K	$1.170M	$1.540M	$230.0K	$360.0K	$240.0K	$310.0K	$600.0K	$740.0K	$840.0K	$720.0K
YoY Change	-20.4%	68.22%	-31.73%	-63.08%	222.64%	220.42%	305.71%	-70.09%	-24.03%	569.57%	-36.11%	50.0%	-22.58%	-48.33%	-18.92%	-11.9%	16.67%
Accrued Expenses	$1.843M	$1.511M	$1.544M	$3.920M	$2.260M	$1.040M	$820.0K	$150.0K	$1.500M	$1.350M	$880.0K	$610.0K	$750.0K	$510.0K	$990.0K	$1.500M	$860.0K	$500.0K
YoY Change	21.97%	-2.14%	-60.61%	73.45%	117.31%	26.83%	446.67%	-90.0%	11.11%	53.41%	44.26%	-18.67%	47.06%	-48.48%	-34.0%	74.42%	72.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$140.0K	$370.0K	$240.0K	$400.0K	$940.0K
YoY Change													-100.0%	-62.16%	54.17%	-40.0%	-57.45%
Long-Term Debt Due								$0.00							$0.00	$200.0K	$950.0K	$190.0K
YoY Change															-100.0%	-78.95%	400.0%
Total Short-Term Liabilities	$7.800M	$8.800M	$6.317M	$11.23M	$17.65M	$6.210M	$5.540M	$860.0K	$2.950M	$3.110M	$1.330M	$1.160M	$1.140M	$1.420M	$2.390M	$2.860M	$3.230M	$2.500M
YoY Change	-11.36%	39.31%	-43.75%	-36.37%	184.22%	12.09%	544.19%	-70.85%	-5.14%	133.83%	14.66%	1.75%	-19.72%	-40.59%	-16.43%	-11.46%	29.2%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$200.0K	$0.00
YoY Change																-100.0%
Other Long-Term Liabilities	$1.266M	$2.666M	$3.618M	$4.560M	$1.100M				$0.00	$120.0K	$660.0K	$0.00	$120.0K	$130.0K	$110.0K	$90.00K	$80.00K	$40.00K
YoY Change	-52.51%	-26.31%	-20.66%	314.55%					-100.0%	-81.82%		-100.0%	-7.69%	18.18%	22.22%	12.5%	100.0%
Total Long-Term Liabilities	$1.266M	$2.666M	$3.618M	$4.560M	$1.100M	$0.00	$0.00	$0.00	$0.00	$120.0K	$660.0K	$0.00	$120.0K	$130.0K	$110.0K	$90.00K	$280.0K	$40.00K
YoY Change	-52.51%	-26.31%	-20.66%	314.55%					-100.0%	-81.82%		-100.0%	-7.69%	18.18%	22.22%	-67.86%	600.0%
Total Liabilities	$9.066M	$11.47M	$9.935M	$15.80M	$18.76M	$6.210M	$5.540M	$860.0K	$2.950M	$3.240M	$1.990M	$1.160M	$1.260M	$1.550M	$2.500M	$2.950M	$3.510M	$2.540M
YoY Change	-20.93%	15.41%	-37.12%	-15.78%	202.09%	12.09%	544.19%	-70.85%	-8.95%	62.81%	71.55%	-7.94%	-18.71%	-38.0%	-15.25%	-15.95%	38.19%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020
Basic Shares Outstanding	43.08M	36.51M	36.18M	29.85M
Diluted Shares Outstanding	43.08M	36.51M	36.18M	29.85M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $9.2966 Million

About BRAINSTORM CELL THERAPEUTICS INC.

Brainstorm Cell Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 29 full-time employees. The company went IPO on 2003-05-28. BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The firm is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. The company has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.

Industry: Biological Products, (No Diagnostic Substances) Peers: Savara Inc Anixa Biosciences Inc CEL SCI CORP CHIMERIX INC Clovis Oncology, Inc. Larimar Therapeutics, Inc. Viracta Therapeutics, Inc. Vor Biopharma Inc.